Latest Conference Coverage

Understanding the ADAPT-SC Results of Subcutaneous Efgartigimod: Tuan Vu, MD

The division director of Neuromuscular Medicine & EMG at USF Health provided an overview of the open-label findings from ADAPT-SC, a phase 3 study assessing subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 3 minutes]

Decreased Neurofilament Light in ATTR Polyneuropathy Observed With Vutrisiran and Patisiran

Vutrisiran and patisiran treatment led to noticeable reductions in neurofilament light, indicating a potential biomarker of treatment response in hATTR amyloidosis patients.

Subcutaneous Efgartigimod PH20 Demonstrates Efficacy for Generalized Myasthenia Gravis in Open Label ADAPT-SC+ Trial

Presented at the 2023 AANEM meeting, new findings suggest that subcutaneous efgartigimod could be a valuable treatment option for patients with myasthenia gravis, with well-tolerated cycles and improved daily living activities.

Open-Label PROPEL Study Results Highlight Longterm Impact of Cipaglucosidase Alfa and Miglustat in Late-Onset Pompe Disease

The phase 3 PROPEL study demonstrated the long-term effectiveness of cipaglucosidase alfa/miglustat in late-onset Pompe disease, with improved 6-minute walk distance and lung function.

The Potential of Nipocalimab as a Treatment for Autoantibody Mediated Diseases: Hong Sun, MD, PhD

The senior director and global compound development team leader at Janssen discussed research on nipocalimab, an investigational agent for patients with myasthenia gravis that's shown promising data to this point. [WATCH TIME: 2 minutes]

Latozinemab Shows No Impact on Disease Progression in C9orf72 Frontotemporal Dementia Despite increasing Progranulin Expression

latozinemab treatment for C9orf72-associated frontotemporal dementia showed no significant impact on disease progression, although the treatment was generally safe and well-tolerated.

The Role of Biomarkers in Myasthenia Gravis Diagnosis and Treatment: Hong Sun, MD, PhD

The senior director and global compound development team leader at Janssen talked about the importance of biomarkers in detecting an earlier diagnosis of myasthenia gravis and the significant unmet medical need for better treatment options. [WATCH TIME: 3 minutes]

NeuroVoices: David Greeley, MD, on AR1001, an Oral PDE5 Inhibitor for Alzheimer Disease

David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.

Designing More Effective Proof-of-Concept Studies for Progressive MS Therapies: Robert J. Fox, MD

The vice-chair for research at Cleveland Clinic’s Neurological Institute discussed the way therapies are currently assessed for progressive MS and the need for disease-specific biomarkers. [WATCH TIME: 3 minutes]

Takeda’s TAK-861 Shows Promise in Improving Wakefulness in Phase 1 Trial Among Healthy Men

Lowering of Amyloid Plaque Through Monoclonal Antibodies Correlated With Better Clinical Benefit, Meta-Analysis Suggests

Results showed that the relative reduction (RR) in CDR-SB at end-of-study was moderately correlated with difference between treated and placebo in Centiloid change.

Reviewing the Phase 2 OVERTURE Results of Gamma Sensory Stimulation Device: Brent Vaughan

The chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]

Alzheimer Agent Simufilam Not Associated With ARIA-E, Phase 3 Reports Show

At 40 weeks, there were no observed cases of ARIA-edema, and new microhemorrhages occurred predominantly in patients with pre-existing conditions.

Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brent Vaughan

The chief executive officer of Cognito Therapeutics provided an in-depth overview of the company’s gamma sensory stimulation device, its mechanism of action, and why it serves as a promising therapy for patients with Alzheimer disease. [WATCH TIME: 5 minutes]

Anti-Amyloid-ß Oligomer Antibody ACU193 Reduces Amyloid Plaques in Dose-Dependent Manner

ACU193 treatment reduced amyloid plaques in early Alzheimer disease patients, suggesting AßOs as a viable target, with safety data and ARIA analysis presented at CTAD 2023.

Combination of Aducanumab Infusion and Focused Ultrasound Accelerates Reduction of Amyloid-ß Plaques

The use of focused ultrasound-mediated blood-brain barrier opening has the potential to advance neurotherapeutics in the treatment of Alzheimer disease and other progreesive neurological disorder impacted by that barrier.

Biogen’s BIIB080 Exhibits Favorable Outcomes in Phase 1b Trial for Early Alzheimer Disease

Patients with mild Alzheimer disease who received high doses of BIIB080 demonstrated improvement in cognitive and functional outcomes compared with placebo, supporting further investigation.

Mechanistic Potential of Pepinemab, a SEMA4D-Blocking Antibody: Terrence L. Fisher, PhD

The senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]

Eisai Plans to Submit BLA for Subcutaneous Lecanemab After Findings Show Promising Results

New subcutaneous lecanemab considered more effective than IV for amyloid plaque removal in Alzheimer disease; FDA application planned by March 2024.

The Complexities of Alzheimer Disease Treatment and Diagnosis in Clinical Trials: Sharon L. Rogers, PhD

The chief executive officer at AmyriAD Therapeutics discussed the limitations of clinical trials assessing potential disease-modifying therapies for Alzhiemer disease including the lack of a diverse patient population and nonthorough clinical assessments for diagnosis. [WATCH TIME: 6 minutes]

Phase 2b RewinD-LB Study Aims to Confirm Neflamapimod’s Potential in Dementia With Lewy Bodies

Findings from the phase 2a AscenD-LB, a study of neflamapimod in patients with mild-to-moderate Alzheimer disease, served as supportive data to guide the phase 2b study.

AXS-05 Shows Reduction in Relapse Risk in Phase 3 ACCORD Trial for Alzheimer Disease Agitation

Findings from the trial demonstrated rapid and sustained clinical response in patients with Alzhiemer disease agitation during the open-label treatment phase and did not show any new safety signals.

Therapeutic Advantages to Using EEG to Assess Alzheimer Agents: Williem de Haan, MD, PhD

The neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]

Cognito’s Gamma Sensory Stimulation Continues to Show Promising Long-term Results in OVERTURE Study of Alzheimer Disease

Over the 18-month treatment period, investigators observed no amyloid-related imaging abnormalities along with continued slowing of disease progression in patients with mild to moderate Alzheimer disease.

Achieving Consensus and Expanding Treatment Horizons in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

The neuroimmunologist at Clínica Alemana de Santiago and the head of the University Center for Multiple Sclerosis at Ramos Mejía Hospital talked about Latin America’s pursuit of expanding treatment options and patient inclusivity as a focus of neurological censuses in NMOSD. [WATCH TIME: 5 minutes]

NeuroVoices: Barry Singer, MD, on Recent Strides in the Treatment and Management of Multiple Sclerosis

The director and founder of The MS Center for Innovations in Care provided perspective on some of the significant strides made in recent years to improve the care and access to affordable treatments for patients with multiple sclerosis.

Shifting Toward Precision Care in Multiple Sclerosis Using Disease Activity Tests and Serum Biomarkers: Michael Y. Sy, MD, PhD

The associate professor of clinical neurology at the University of California, Irvine School of Medicine, discussed the use of a multiple sclerosis disease activity test and serum biomarkers in improving the landscape of care for patients. [WATCH TIME: 5 minutes]

Potential Role of Glial Fibrillary Acidic Protein in Progressive Multiple Sclerosis: Robert J. Fox, MD

The vice-chair for research at Cleveland Clinic’s Neurological Institute provided commentary on the expanded research of GFAP in multiple sclerosis and whether certain biomarkers may predict treatment response. [WATCH TIME: 8]

Key Clinical Red Flags for Differential Diagnosis of Multiple Sclerosis: Georgina Arrambide, MD, PhD

The clinical neurologist at the MS Center of Catalunya provided perspective on her presentation from MSMilan 2023, focusing in on key factors when diagnosing multiple sclerosis from other similarly presenting disorders. [WATCH TIME: 5 minutes]

Possibilities of Measuring Cognitive Progression Independent of Relapses in MS: Tom Fuchs, MD, PhD

The research fellow at the Amsterdam University Medical Center provided thoughts on the possibilities of assessing cognitive decline in clinical settings for patients with multiple sclerosis. [WATCH TIME: 5 minutes]